Earnings Releases·Nov 9, 2026, 7:05 AM ET

Aura Biosciences — Third Quarter 2026 Earnings Summary

**Financial Results:** Net loss widened to $32.1 million for Q3 2026 from $26.1 million in the prior year period, driven by a $4.5 million restructuring charge and increased R&D expenses of $24.7 million; total operating expenses for the nine-month period rose to $118.0 million from $85.6 million.
**Balance Sheet & Liquidity:** Cash, cash equivalents, and marketable securities totaled $297.2 million as of September 30, 2026, providing a runway into the first half of 2029, while total stockholders' equity grew to $287.4 million from $136.9 million at the end of 2025.
**Clinical Progress:** All 108 participants in the Phase 3 CoMpass trial have completed treatment and are in the 24-month follow-up period, with topline data for the primary endpoint expected in the second half of 2027.
**Strategic Initiatives:** The company established a new supply relationship with an industry-leading CDMO to secure manufacturing capacity for bel-sar and incurred restructuring charges to align resources behind its ocular oncology portfolio.